Home
Issues
Aim & Scope
Open Access
Indexing
Why publish with us
Contact
Editorial Board
Instructions to Authors (PDF)
Manuscript Types
Manuscript Formatting
How to submit
Preprints
Authorship & COI
Principles of Transparency Checklist
Publication Ethics and Publication Malpractice Statement
Data Policies
EDITORIAL
Stem cells and covid-19
| 1 | Department of Pneumonology, Serres General Hospital, Serres, Greece |
| 2 | Medical School, National and Kapodistrian University of Athens, Athens, Greece |
CORRESPONDING AUTHOR
Demosthenes Bouros
Medical School, National and Kapodistrian University of Athens, Athens, Greece Athens Medical Center, Kifissias 58, Maroussi 15125, Athens, Greece
Medical School, National and Kapodistrian University of Athens, Athens, Greece Athens Medical Center, Kifissias 58, Maroussi 15125, Athens, Greece
Pneumon 2020;33(1):1–3
KEYWORDS
CONFLICTS OF INTEREST
None
REFERENCES (23)
1.
Tzouvelekis Α, Antoniadis Α, Bouros D. Stem cell therapy in pulmonary fibrosis. Curr Opin Pulm Med 2011; 17:368-73.
2.
Antoniadis A, Stogiou P. Repair of respiratory system lesions using stem cells. Pneumon 2009; 22:18-24.
3.
Tzouvelekis A, Paspaliaris V, Koliakos G, et al. A prospective, non-randomized, no placebo-controlled, phase Ιb clinical trial to study the safety of the adipose derived stromal cells – stromal vascular fractio in idiopathic pulmonary fibrosis. J Transl Med 2013; 11:171.
4.
Tzouvelekis A, Koliakos G, Ntolios P, et al. Stem cell therapy for idiopathic pulmonary fibrosis: a protocol proposal. J Transl Med 2011;9:182.
5.
Tzouvelekis A, Toonkel R, Karampitsakos T, et al. Mesenchymal stem cells for the treatment of idiopathic pulmonary fibrosis. Front Med (Lausanne). 2018;5:142.
6.
Tzouvelekis A, Ntolios P, Bouros D. Stem cell treatment for chronic lung diseases. Respiration 2013; 85:179-92.
7.
Bouros D, Laurent G. Regenerative medicine and stem cells: prometheus revisited. Respiration 2013; 85:1-2.
8.
Tzouvelekis A, Laurent G, Bouros D. Stem cell therapy in chronic obstructive pulmonary disease. Seeking the Prometheus effect. Curr Drug Targets 2013;14:246-52.
9.
Tzouvelekis A, Bouros D. Embryonic stem cells for lung fibrosis Is it the Prometheus myth or the Pandora's Box? Sarcoidosis Vasc Diffuse Lung Dis 2013;30:246-8.
10.
Ntolios P, Manoloudi E, Tzouvelekis A, et al. Longitudinal outcomes of patients enrolled in a phase Ib clinical trial of the adipose-derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis. Clin Respir J 2018;12:2084-9.
11.
Khoury M, Cuena J, Cruz FF, et al. Current status of cell-based therapies for respiratory virus infections: Applicability to COVID-19. Eur Respir J 2020; 55: in press.
12.
Gentile P, Sterodimas A. Adipose-derived stromal stem cells (ASCs) as a new regenerative immediate therapy combating coronavirus (COVID-19)-induced pneumonia. Expert Opinion on Biological Therapy 2020.
13.
Golchin A, Seyedjafari E, Ardeshirylajimi A. Mesenchymal stem cell therapy for COVID-19: Present or future. Stem cell reviews and reports 2020; in press 13 April 2020.
14.
Lopes-Pacheco M, Robba C, Rieken P, Rocco M. Current understanding of the therapeutic benefits of mesenchymal stem cells in acute respiratory distress syndrome. Cell Biol Toxicol 2020; 36:83-102.
15.
Worthington EN, Hagood JS. Therapeutic use of extracellular vesicles for acute and chronic lung disease. Int J Mol Sci 2020; 21:2318.
16.
O’Driscoll L. Extracellular vesicles from mesenchymal stem cells as a Covid-19 treatment. Drug Discov Today 2020.
17.
Atluri S, Manchikanti L, Hirsch JA. Expanded umbilical cord mesenchymal stem cells (UC-MSCs) as a therapeutic strategy in managing critically Ill COVID-19 patients: The case for compassionate use. Pain Physician 2020; 23:E71-E83.
18.
Leng Z, Zhu R, Hou W, et al. Transplantation of ACE2(-) mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis 2020; 11:216-28.
19.
Khoury M, Cuenca J, Cruz FF, et al. Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19. EurRespir J 2020; 55:2000858.
20.
Shetty AK. Mesenchymal stem cell infusion shows promise for combating coronavirus (COVID-19)- induced pneumonia. Aging Dis 2020; 11:462-4.
21.
Sengupta V, Sengupta S, Lazo A, et al. Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19. Stem Cells Dev 2020.
22.
Gentile P, Sterodimas A. Adipose-derived stromal stem cells (ASCs) as a new regenerative immediate therapy combating coronavirus (COVID-19)-induced pneumonia. Expert Opin Biol Ther 2020 Apr 29:1-6.
23.
Zumla A, Wang FS, Chang C, et al. Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of mesenchymal stromal (stem) Cell (MSC) therapy - Achieving global consensus and visibility for cellular host-directed therapies. Int J Infect Dis 2020; 96:431-9.
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.